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Abstract: Introduction: Appropriate pain relief enhances patient satisfaction and reduces patient anxiety. This study
aimed to compare oral oxycodone with intravenous (IV) morphine sulfate (MS) in pain management of acute
limb trauma. Methods: In this randomized double-blind clinical trial, patients over 14 years old, with acute
isolated limb trauma were randomized to receive either 5mg IV MS or 5 mg oral oxycodone. Pain intensity and
adverse effects of medications were recorded 0, 30 and 60 minutes after drug administration and compared
between the groups. Results: 58 patients were studied. Pain intensity was similar between the two studied
groups at 30 minutes (P = 0.834) and 60 minutes (P = 0.880) after drug administration. Furthermore, there was
no significant difference between the two groups regarding decrease in pain within the defined time interval.
Drowsiness was reported more frequently in MS group after 30 minutes (p = 0.006). Patients in MS group asked
for more rescue analgesia. Other adverse effects were similar in both groups. Conclusion: Oral oxycodone is as
effective as IV morphine sulfate in treatment of acute musculoskeletal pain following blunt limb trauma.
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1. Introduction
Pain is an unpleasant emotional and sensory experience and
the most common cause of emergency department (ED) vis-
its. In the United States, almost 40 million ED visitors looked
for analgesics for relief of acute pain in one year (1, 2). Ap-
propriate pain relief enhances patient satisfaction and re-
duces patient anxiety (2, 3). Hence, effective management
of acute pain is one of the most important aspects of emer-
gency physicians’ practice (2, 4).
One acceptable approach for pain management in the ED
is administration of effective drugs with minimal side ef-
fects, through an appropriate route. Several therapeutic
agents have been used including acetaminophen (Paraceta-
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mol), non-steroidal anti-inflammatory drugs (NSAIDs), opi-
oids and synthetic drugs with narcotic properties (3). Mild
to moderate pain is usually controlled by non-opioid agents,
while opioid analgesics are used to reduce moderate-to-
severe pain (5). Intravenous (IV) morphine sulfate (MS) is
a common and effective analgesic agent, used for manage-
ment of moderate to severe pain in ED (6-8). However, some
potential side effects such as respiratory and central nervous
system depression, nausea and vomiting and pruritus have
been reported (6-8). Yet another feature that can limit the
utility of MS as an ideal analgesic in the ED is its IV form
of administration. Therefore, agents that do not require IV
line placement could potentially be the preferred approach
for initiation of pain treatment (7).
Oxycodone is a semisynthetic analgesic opioid and an ago-
nist of mu, kappa and delta receptors (1, 5, 6, 9). Mu recep-
tors are known to be responsible for analgesia (µ1), sedation,
euphoria and its side effects include pruritus, vomiting and
This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).
Downloaded from: www.jemerg.com
P. Eizadi et al. 2
respiratory depression (µ2). Furthermore, kappa receptors
are responsible for analgesia, dyspnea, dysphoria, urinary re-
tention, and meiosis while delta receptors have spinal anal-
gesic effects (10). Oxycodone is a potent opioid with high oral
bioavailability, rapid absorption and predictable effects (1, 6,
9). Compared to morphine, oxycodone has a greater anal-
gesic potency and a shorter half-life. Its onset of action is 1
hour after administration and peak plasma concentration is
achieved within 90 minutes (1, 5, 6).
Although oxycodone and morphine share some characteris-
tics such as increased tolerance and addictive potential, (1)
easy titration, predictable metabolism, less toxicity and less
sedation distinguish oxycodone from morphine (6, 9, 11).
Oxycodone produces less hallucination, nausea and pruritus
compared to morphine and it does not affect arterial pres-
sure and heart rate (1, 5, 6).
An overview of prior literature highlighted the lack of studies
about use of oral oxycodone in the field of acute trauma. The
majority of reports are about chronic pain or in settings other
than the ED (12). This study was designed to compare ease
of administration, efficacy and safety of oral oxycodone with
those of IV morphine sulfate in sequential time points after
drug administration in patients with acute limb trauma.
2. Methods
2.1. Study design and setting
This is a randomized, double-blind placebo controlled clini-
cal trial that was approved and monitored by the ethics com-
mittee of Tehran University of Medical Sciences (ethics ref-
erence number: 54352). The study was conducted in the
emergency department of a tertiary teaching hospital (Imam
Khomeini), Tehran, Iran, From July 2014 to March 2015. The
trial was officially registered in IRCT.ir (registration number:
IRCT201204089387N2). Written informed consent was ob-
tained from all patients before enrolment.
2.2. Participants
Eligible participants were adult patients aged 14 or above
with moderate to severe pain (Numerical Rating Scale [NRS]
more than 3) following isolated limb trauma. We excluded
patients with altered consciousness, severe chronic disease
(liver, kidney and respiratory), previous history of allergy to
opioids, recent opioid use and pregnant patients.
2.3. Intervention:
Participants were randomized to receive either 5 mg oral
oxycodone hydrochloride plus 5ml IV injection of normal
saline or 5 ml equivalent to 5 mg injection of IV MS and
oral placebo. Block randomization using computer gener-
ated blocks of four was used to assign patients to each group.
Drugs were prepared and sealed in consecutively numbered
envelops by a research assistant who was not involved in
drug administration. Patients’ enrollment, drug administra-
tion and data collection were done by another trained re-
search assistant. Research assistants were medical students
and they were trained for the study objectives. Patients and
assistants who administrated drugs and collected data re-
mained blinded to study groups during the study.
2.4. Data gathering
Prior to drug administration demographic features and
mechanism of trauma were registered in data collection
sheets. Participants were asked to score the pain severity
from 0 to 10. Eligible patients received either drug. Data were
collected at 0, 30 and 60 minutes after patients received anal-
gesics.
2.5. Outcome assessment
Primary outcome of this study was pain relief and was as-
sessed by NRS at exact time points. Secondary outcomes in-
cluding changes in blood pressure, dizziness, pruritus, nau-
sea and vomiting were also monitored and registered simul-
taneously.
2.6. Statistical Analysis
Based on previous studies, which showed standard deviation
of 1.7 in the population (2), and considering an effect size
of 1.3, we estimated that sample size of 28 patients in each
group will give a power of 80% and two side type one error of
5% to detect a significant difference. Descriptive analysis was
used to compare basic features in the two groups. One way
ANOVA and general linear mode were used to analyze out-
comes between and within groups. The study result analysis
was based on per protocol method. Data were analyzed us-
ing SPSS 20 statistical software and intension to treat analysis
approach.
3. Results
3.1. Characteristics of the study population
80 patients were assessed for eligibility; 20 of which were
excluded from the study. Sixty patients were enrolled and
randomly allocated to either oxycodone or MS group. Trial
subjects flow is shown in figure 1. Participants’ main charac-
teristics are shown in Table 1. Baseline characteristics were
similar between the two groups.
3.2. Comparison of two groups
Mean pain score in MS group was 8.32 ± 1.36 at the time
0, reached 5.71 ± 2.39 at 30 minutes, and 4.75 ± 2.24 at 60
minutes after drug administration (p < 0.001). Also mean
pain score in oxycodone group was 7.35 ± 1.55 at the time
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Table 1: Baseline Characteristics of studied participants
Characteristics Morphine sulfate (n=28) Oxycodone (n=30) P Value
Age
Mean ± standard deviation 32.86 ± 15.39 29.27 ± 9.35 0.432
Sex
Male 23 (82.10) 20 (66.67) 0.179
Female 5 (17.90) 10(33.33)
Mechanism of injury
Direct trauma 1 (3.60) 5 (16.70)
MVA 10 (35.70) 13 (43.30) 0.226
Falling 14 (50.00) 11 (36.70)
CPA 3 (10.7) 1 (3.30)
Data were presented as mean ± standard deviation or frequency (%).
MVA: motor vehicle accidents; CPA: car pedestrian accident
Table 2: Comparison of pain severity between groups in 0, 30, and 60 minutes after drug administration
Time (minute) Median Mean ± SD SEM P value
0
Morphine Sulfate 9 8.32 ± 1.36 0.257 0.045
Oxycodone 8 7.53 ± 1.55 0.282
30
Morphine Sulfate 6 5.71 ± 2.39 0.450 0.834
Oxycodone 6 5.83 ± 1.89 0.346
60
Morphine Sulfate 4 4.75 ± 2.24 0.422 0.880
Oxycodone 5 4.83 ± 1.93 0.352
Differences 0-30
Morphine Sulfate -2.8214 1.96362 0.37109 0.078
Oxycodone -1.7333 1.55216 0.28338
Differences 30-60
Morphine Sulfate -0.7857 0.99469 0.18798 0.903
Oxycodone -0.9667 0.92786 0.16940
Differences 0-60
Morphine Sulfate -3.5000 1.68874 0.31914 0.110
Oxycodone -2.7000 1.91455 0.34955
SEM, standard error of mean; SD: standard deviation.
Table 3: Frequency of adverse event occurrence in the studied groups
Adverse event Oxycodone Morphine sulfate P value
Hypotension
30 minute 7 (23.30) 3 (10.70) 0.301
60 minute 8 (26.70) 4 (14.30) 0.336
Nausea
30 minute 2 (6.70) 6 (21.40) 0.138
60 minute 2 (6.70) 4 (14.30) 0.415
Dizziness
30 minute 3 (10.00) 12 (42.90) 0.006
60 minute 11 (36.70) 11 (39.30) 1.000
Rescue analgesic
30 minute - - -
60 minute 1(3.30) 8(28.60) 0.011
0, reached 5.83 ± 1.89 at 30 minutes, and 4.83 ± 1.93 at 60
minutes after drug administration (p < 0.001). Although there
was a 0.81 difference in pain score between the two study
groups at the time 0, there was no significant difference be-
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tween groups 30 and 60 minutes after administration of med-
ications (Table 2, figure 2).
3.3. Secondary outcomes
Dizziness was reported more frequently in morphine sul-
fate group compared to oxycodone group. Eight participants
asked for rescue analgesic in morphine group, while only one
patient asked for more analgesia in oxycodone group. Other
adverse effects were similar in both groups (Table 3). There
were no cases of seizure, respiratory depression or loss of
consciousness. No naloxone was administrated during the
study.
4. Discussion:
The results of the current study demonstrate that oral oxy-
codone is as effective as IV MS in relieving pain of patients
with acute limb trauma. Considering pain score at the time
points of 30 minutes and 60 minutes after drug administra-
tion, no significant differences were observed between the
two groups. To minimize the effect of the mentioned dispar-
ity, we analyzed the amount of decrease in pain score in spe-
cific time intervals. The result was similar and the analgesic
effects of these two opioids were comparable.
A limited number of studies have compared oxycodone with
morphine sulfate. The findings of our study are compatible
with the study conducted by Miner et al. In their study, pa-
tients received either 0.125 mg/kg oral solution of oxycodone
or 0.1 mg/kg IV morphine sulfate. Pain score, adverse ef-
fects, onset of action and time to administration of drugs
were assessed in patients with acute musculoskeletal pains
in sequential time intervals (7). Result of that study, similar
to our findings, highlighted that the pain scores of the two
study groups were similar 30 minutes after drug administra-
tion. The results of our study are also similar to the study by
Pedersen et al. Although the results were comparable, the de-
sign of their study was different from ours. They studied anal-
gesic effects of morphine and oxycodone, both in dose of 0.1
mg/kg, 4 hours after percutaneous kidney stone surgery (11).
Pain score and side effects of medications were assessed ev-
ery 15 minutes. Oxycodone appeared to be similar to mor-
phine in analgesia 4 hours after surgery.
In our study, drowsiness was reported more frequently at
time point of 30 minutes by patients who received morphine
sulfate while the distinction between the two groups was less
obvious at time point of 60 minutes. Kalso, in a study in
1991, mentioned more drowsiness in patients who received
morphine for post-surgical pain treatment compared to pa-
tients who received oxycodone (13). Other adverse effects
were similar in both groups according to our study. Patients
in morphine sulfate group asked for more rescue analgesic.
Figure 1: study participants’ flow diagram.
Figure 2: Pain score changes during study period (p > 0.05).
5. Limitations
We believe that our study faced a number of limitations.
Firstly, the sampling of our patients could have been affected
by the following conditions: in crowded EDs most patients
with acute isolated limb trauma are managed as outpatients
and they receive prescribed analgesics at home. Our study
population consisted of admitted patients and hence the re-
sults may not be applicable to an outpatient population. Fur-
thermore, we conducted the study in a single center. Sec-
ondly, we administerated a single dose of 5mg for both mor-
phine sulfate and oxycodone groups instead of adjusting the
dosage to the weight. Although the dosage effectively re-
duced pain; the fact is that the side effects of opioids occur
in higher doses. For more accurate comparison of side ef-
fects between the two drugs, higher doses should be admin-
istrated. Thirdly, we used NRS for pain scoring. It is possible
that some patients mentioned higher pain score in order to
accelerate the services they would receive. Finally, although
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we had randomly allocated the patients to either group, the
final groups were significantly different regarding sex. As a re-
sult of our randomization, there were significant discordance
between sex distribution of the two groups and this can be
considered as a confounding factor. Considering the fact that
there is potential sex difference in analgesic effects of opioids
(14-18), result of this study should be interpreted cautiously.
6. Conclusion
To sum up, oral oxycodone is as effective as IV morphine sul-
fate in management of acute pain following limb trauma. It
can be considered as an appropriate alternative for IV mor-
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